C.R. Bard Stock To Go Ex-dividend Tomorrow (BCR)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- The ex-dividend date for C.R. Bard (NYSE: BCR) is tomorrow, October 18, 2012. Owners of shares as of market close today will be eligible for a dividend of 20 cents per share. At a price of $102.09 as of 9:30 a.m. ET, the dividend yield is 0.8%.

The average volume for C.R. Bard has been 529,200 shares per day over the past 30 days. C.R. Bard has a market cap of $8.49 billion and is part of the health care sector and health services industry. Shares are up 19.6% year to date as of the close of trading on Tuesday.

C. R. Bard, Inc. and its subsidiaries design, manufacture, package, distribute, and sell medical, surgical, diagnostic, and patient care devices worldwide. The company has a P/E ratio of 17.2, equal to the average health services industry P/E ratio and below the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates C.R. Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, notable return on equity, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full C.R. Bard Ratings Report.

See our dividend calendar or top-yielding stocks list.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

Deals of the Week: Waiting for Clarity

Merger Buzz Drives Akorn to Top of Health Chart in April

Deals of the Week: Reason for Optimism

Good Medicine Makes for 3 Good Charts